Hypoxia and Glucose Metabolism in Malignant Tumors: Evaluation by [ 18F]Fluoromisonidazole and [18F]]Fluorodeoxyglucose Positron Emission Tomography Imaging

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2245-2252

  Rajendran, Joseph G ^a,b   Mankoff, David A ^a   O'Sullivan, Finbarr ^d   Peterson, Lanell M ^a   Schwartz, David L ^a,c   Conrad, Ernest U ^b   Spence, Alexander M ^b   Muzi, Mark ^a   Farwell, D Greg ^b   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Vet Admin Puget Sound Hlth C S   (United States)

^d UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DRUG UPTAKE; GLIOBLASTOMA; GLUCOSE METABOLISM; GLYCOLYSIS; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; IMAGE ANALYSIS; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; STATISTICAL ANALYSIS;

ANOXIA; CELL LINE, TUMOR; FLUORODEOXYGLUCOSE F18; GLUCOSE; GLYCOLYSIS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; NEOPLASM METASTASIS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 11144353536     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0688-3     Document Type: Article

References (51)

1. 2 tension measurments. Cancer Res 1991;51:6098-102.
2. 2 tension measurements. Cancer Res 1991;51:3316-22.
3. Brown MJ. The hypoxic cell: a target for selective cancer therapy. Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1999;59:5863-70.
4. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-68.
5. Sutherland RM. Tumor hypoxia and gene expression: implications for malignant progression and therapy. Acta Oncol 1998;37:567-74.
6. Adam M, Gabalski EC, Bloch DA, et al. Tissue oxygen distribution in head and neck cancer patients. Head Neck 1999;21:146-53.
7. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Biol Phys 1996;36:417-28.
8. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
9. Brizel DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1994;30:635-42.
10. Nordsmark M, Loncaster J, Chou SC, et al. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. Int J Radiat Oncol Biol Phys 2001;49:581-6.
11. Knowles HJ, Harris AL. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res 2001;3:318-22.
12. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-9.
13. Valk P, Mathis C, Prados M, Gilbert J, Budinger T. Hypoxia in human gliomas: demonstration by PET with flouorine-18-fluoromisonidazole. J Nucl Med 1992;33:2133-7.
14. Eary JF, Conrad EU. Positron emission tomography in grading soft tissue sarcomas. Semin Musculoskelet Radiol 1999;3:135-8.
15. Stokkel MP, ten Broek FW, van Rijk PP. The role of FDG PET in the clinical management of head and neck cancer. Oral Oncol 1998;34:466-71.
16. Visser FC. Imaging of cardiac metabolism using radiolabelled glucose, fatty acids and acetate. Coron Artery Dis 2001;12(Suppl 1):S12-8.
17. Semenza GL, Artemov D, Bedi A, et al. "The metabolism of tumours": 70 years later. Novartis Found Symp 2001;240:251-60; discussion 260-254.
18. Racker E, Spector M. Warburg effect revisited: merger of biochemistry and molecular biology. Science (Wash. DC) 1981;213:303-7.
19. Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001;42:170-5.
20. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis, and proliferation. Am J Clin Oncol 2001;24:467-72.
21. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. J Nucl Med 1996;37:502-6.
22. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20:379-87.
23. Walenta S, Snyder S, Haroon ZA, et al. Tissue gradients of energy metabolites mirror oxygen tension gradients in a rat mammary carcinoma model. Int J Radiat Oncol Biol Phys 2001;51:840-8.
24. 18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999;40:1072-9.
25. Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer (Phila.) 1984;54:2441-9.
26. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91.
27. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212.
28. Rajendran JG, Wilson D, Conrad EU, et al. F-18 FMISO and F-18 FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression Eur J Nucl Med 2003;30:695-704.
29. 18F]fluoro-2-deoxy-D-glucose. Acta Oncol 2000;39:629-37.
30. Spence AM, Muzi M, Graham MM, et al. Analysis of the deoxyglucose lumped constant in human malignant gliomas. Ann Neurol 1991;30:271-2.
31. Kallinowski F, Schlenger KH, Kloes M, Stohrer M, Vaupel P. Tumor blood flow: the principal modulator of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in vivo. Int J Cancer 1989;44:266-72.
32. Lewellen TK, Kohlmeyer SG, Miyaoka RS, et al. Investigation of the count rate performance of the General Electric Advance positron emission tomograph. IEEE Trans Nucl Sci 1995;42:1051-7.
33. DeGrado TR, Turkington TG, Williams JJ, et al. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994;35:1398-1406.
34. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
35. Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA. Radiosynthesis of of fluorine-18 fluoromisonidazole. J Nucl Med 1989;30:343-50.
36. Rajendran JG, Krohn KA. Imaging tumor hypoxia. In: Bailey DL, Townsend DW, Valk PE, Maisey MN, editors. Positron emission tomography, principles and practice. London: Springer Verlag; 2002. p. 689-95.
37. Minoshima S, Berger KL, Lee KS, Mintun MA. An automated method for rotational correction and centering of three-dimensional functional brain images. J Nucl Med 1992;33:1579-85.
38. Rajendran J, Lanell P, Schwartz DS, et al. [F-18] FMISO PET hypoxia imaging in head and neck cancer: heterogeneity in hypoxia. Primary tumor vs lymph nodal metastases J Nucl Med 2002;43:73P.
39. Pedersen MW, Holm S, Lund EL, Hojgaard L, Kristjansen PE. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia 2001;3:80-7.
40. Denekamp J, Dasu A. Inducible repair and the two forms of tumour hypoxia: time for a paradigm shift. Acta Oncol 1999;38:903-18.
41. Erecinska M, Nelson D, Deas J, Silver IA. Limitation of glycolysis by hexokinase in rat brain synaptosomes during intense ion pumping. Brain Res 1996;726:153-9.
42. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149-54.
43. Kitagawa Y, Sano K, Nishizawa S, et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging 2003;30:63-71.
44. Spence AM, Muzi M, Krohn KA. Molecular imaging of regional brain tumor biology. J Cell Biochem Suppl 2002;39:25-35.
45. 18F]-D-glucose. Cancer (Phila.) 1998;82:2227-34.
46. Esumi H, Izuishi K, Kato K, et al. Hypoxia and nitric oxide treatment confer tolerance to glucose starvation in a 5′-AMP-activated protein kinase-dependent manner. J Biol Chem 2002;277:32791-8.
47. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000;6:157-62.
48. Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: the Mallinckrodt experience. Int J Cancer 2000;90:92-103.
49. Pauwels EK, Ribeiro MJ, Stoot JH, et al. FDG accumulation and tumor biology. Nucl Med Biol 1998;25:317-22.
50. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995;36:1625-32.
51. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with (60)Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233-8.